AlphAIAlphAI — Financial news for AI agents
investing.comNOV 22 min read$TEM

Needham raises Tempus AI stock price target to $89 on data growth

Needham raised its price target for Tempus AI (NASDAQ:TEM) to $89 from $75, citing strong Q3 results. Revenue grew 50% over the last year, driven by data business. Tempus reported $411.5M in Q3 revenue, beating estimates, and achieved positive adjusted EBITDA of $25.6M. The company also raised its full-year 2026 revenue outlook to $1.60-$1.605B.

Original reporting
investing.com
Published Nov 2, 2026, 4:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 5:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$TEM
Bullish
high confidence
Mentioned
$TEM
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$TEMBullishMed
01

Why it matters

The earnings beat and raised guidance, combined with a higher analyst price target, provide a catalyst for short‑term price appreciation.

02

Market read

The report delivers fresh earnings data and an upgraded target, offering traders a timely signal to consider buying pressure on TEM.

03

What to watch

Potential regulatory scrutiny on data usage and competition from larger players could temper upside.

Relevance 8/10Novelty 8/10Timing: today

Background

Tempus AI, a genomics and data analytics company, announced its Q3 2026 results, showing strong revenue growth and a first quarter of positive adjusted EBITDA.

Company-level read

Ticker impact

$TEMBullishHigh confidence
Context

Tempus AI reported Q3 2026 earnings beating expectations, posted positive adjusted EBITDA and raised its full-year revenue outlook, prompting Needham to lift its price target to $89.

Expected impact

likely upward pressure as investors price in the earnings beat and higher target.

Evidence & confidence

Revenue and EBITDA exceeded consensus, and the price target increase signals analyst confidence, which typically drives buying.

Market effects

Sector

Strong earnings may lift other genomics and data‑analytics firms as the sector benefits from demonstrated growth.

Regional

Positive for US biotech and health‑tech stocks, reinforcing investor appetite in the domestic market.

Global

Highlights the expanding role of data‑driven diagnostics worldwide, potentially influencing global health‑tech valuations.

Counterpoint

What could challenge this read

The valuation may already be stretched; rapid growth could be unsustainable, prompting a pull‑back.

Key entities

  • company
    Tempus AI Inc

    NASDAQ‑listed genomics and data analytics firm.

  • analyst
    Needham

    Equity research firm that raised the price target.

Read at source← All news

StoryTempus AI posts record Q3 revenue, first adjusted profit and raises full‑year outlook

Also covered by

6 outlets

Related articles

NOV 3
$TEMLow

Jefferies upgrades Tempus AI stock rating to hold, raises price target to $70

Jefferies upgraded Tempus AI (TEM) from Underperform to Hold, raising its price target to $70. The stock, currently at $78.48, has gained 43% in six months. The firm cited strong revenue growth, strategic collaborations, and FDA approval plans. Tempus reported Q3 2026 earnings of $0.07 per share, beating estimates, with revenue up 23% to $411.5 million. Needham raised its price target to $89, citing data business growth.

investing.com2 min
NOV 3
$TEMMed

Tempus AI Inc (TEM) Q3 2026 Earnings Call Highlights: Revenue Jumps 23%

Tempus AI Inc (TEM) reported Q3 2026 revenue of $411M, up 23%. CEO Lefkofsky expects sustainable 25%+ growth, with oncology and data segments driving performance. The company anticipates mid-2027 breakeven for Personalis' MRD test and predicts strong market share in MRD. Tempus also highlighted long-term data business commitments and AI-driven customer stickiness.

finance.yahoo.com2 min
NOV 2
$TEMMedAI 8/10

Tempus AI (TEM): Oncology Volume Surge and Data Licensing Bookings Signal a Profitable Inflection

Tempus AI (TEM) reported Q3 2026 revenue of $411.5M, up 23% YoY, with adjusted EBITDA of $25.6M. Oncology revenue grew 28% to $172.6M, while Data and Applications revenue increased 33% to $108.1M. The company raised full-year revenue guidance to $1.60B-$1.605B and expects near-term catalysts from reimbursement improvements and the pending $1.7B Personalis acquisition.

news.alphastreet.com7 min